Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab

Clinical Rheumatology

Volumn 34, Issue 6, 2015, Pages 1141-1143

  Cantarini, Luca ^a   Lopalco, Giuseppe ^b   Vitale, Antonio ^a   Coladonato, Laura ^b   Rigante, Donato ^c   Lucherini, Orso Maria ^a   Lapadula, Giovanni ^b   Iannone, Florenzo ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Beh et s disease (BD); Genital ulcers; Golimumab; Oral aphthosis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADULT; APHTHOUS STOMATITIS; BEHCET DISEASE; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; FOLLICULITIS; FOLLOW UP; GENITAL ULCER; HUMAN; KNEE ARTHRITIS; PAPULE; PARADOXICAL DRUG REACTION; PARADOXICAL MUCOCUTANEOUS FLARE; PRIORITY JOURNAL; PUSTULE; RECURRENT DISEASE; RELAPSE; REVIEW; TREATMENT RESPONSE; BEHCET SYNDROME; CHEMICALLY INDUCED; DISEASE COURSE; DRUG ERUPTIONS; STOMATITIS, APHTHOUS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; DISEASE PROGRESSION; DRUG ERUPTIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; METHYLPREDNISOLONE; RECURRENCE; STOMATITIS, APHTHOUS;

EID: 84929951625     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2589-z     Document Type: Review

References (25)

1. Zierhut M, Mizuki N, Ohno S, Inoko H, Gül A, Onoé K et al (2003) Immunology and functional genomics of Behçet’s disease. Cell Mol Life Sci 60:1903–1922
2. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341:1284–1291
3. McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3:e297
4. Kotter I, Hamuryudan V, Ozturk ZE, Yazici H (2010) Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 22:278–283
5. Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol 30:S115
6. Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. (2013) Anakinra treatment in drug-resistant Behçet’s disease: a case series. Clin Rheumatol [Epub ahead of print].
7. Alpsoy E (2005) Behçet’s disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol 23:532–539
8. Tunç R, Uluhan A, Melikoğlu M, Ozyazgan Y, Ozdoğan H, Yazici H (2001) A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet’s syndrome. Clin Exp Rheumatol 19:S45–S47
9. Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M et al (2012) A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22:298–302
10. Urbaniak P, Hasler P, Kretzschmar S (2012) Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 30:S73–S75
11. Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, et al. (2013) Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab. Immunol Res 56:390–397
12. Suzuki Kurokawa M, Suzuki N (2004) Behcet’s disease. Clin Exp Med 4:10–20
13. Zhou ZY, Chen SL, Shen N, Lu Y (2012) Cytokines and Behçet’s disease. Autoimmun Rev 11:699–704
14. Pipitone N, Olivieri I, Padula A, D’angelo S, Nigro A, Zuccoli G et al (2008) Infliximab for the treatment of neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum 59:285–290
15. Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61–70
16. Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M (2009) Safety and efficacy of etanercept in children with juvenile-onset Behcet’s disease. Int J Immunopathol Pharmacol 22:551–555
17. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM (2007) Adalimumab: a new modality for Behçet’s disease? Ann Rheum Dis 66:565–566
18. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A (2005) Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52:2513–2518
19. Diamantopoulos AP, Hatemi G (2013) Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford) 52:1923–1924
20. Shapiro LS, Farrell J, Borhani Haghighi A (2012) Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clin Neurol Neurosurg 114:297–298
21. Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N (2003) Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol 73:713–721
22. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V et al (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274:1379–1383
23. Lee EG, Mickle-Kawar BM, Gallucci RM (2013) IL-6 deficiency exacerbates skin inflammation in a murine model of irritant dermatitis. J Immunotoxicol 10:192–200
24. Ono I, Gunji H, Zhang JZ, Maruyama K, Kaneko F (1995) A study of cytokines in burn blister fluid related to wound healing. Burns 21:352–355
25. Borhani Haghighi A, Safari A (2008) Tocilizumab may be a potential addition to our weapons against neuro-Behçet’s disease. Med Hypotheses 71:156–157